Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs Smith & Nephew plc — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $36.08 (market cap $1.02B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 10.9× iShares S&P GSCI Commodity-Indexed Trust ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares S&P GSCI Commodity-Indexed Trust ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares S&P GSCI Commodity-Indexed Trust ETF for 40 Days and Smith & Nephew plc for 121 Days on average.
| GSG | SNN | |
|---|---|---|
Market Cap | $1.02B | $11.10B |
Volume | 1,256,221 | 1,051,703 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.15 | $37.17 |
52-Week Low | $22.45 | $26.42 |
Typical Hold Time | 40 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSG trades at $36.08, up 1.23% with neutral technical signals. The company reported strong 2024 results with $51.25M revenue and $69.99M net income, though cash flow turned negative at -$932.80K. Assets remain robust at $968.15M with minimal debt, while recent news highlights commodity market volatility and energy sector exposure as key drivers.
Outlook remains cautious due to commodity price sensitivity and geopolitical risks, though strong profitability and clean balance sheet provide stability. Analyst sentiment is mixed with neutral ratings prevailing, suggesting limited near-term catalysts beyond broader commodity trends.
Smith+Nephew (SNN) trades at $26.96, near its 52-week low, with bearish technical signals despite recent earnings beats. The company shows strong fundamentals with revenue growth to $6.16B in 2025 and improving profit margins of 10.08%. Recent product launches in trauma care and surgical robotics highlight innovation, but analyst sentiment remains cautious with 65% hold ratings.
Investment outlook is mixed: solid fundamentals and product pipeline offer upside, but technical weakness and analyst skepticism pose near-term risks. Key catalysts include execution on new product adoption and margin expansion, while risks involve competitive pressures and leadership transitions following the CFO's departure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
